Compare Infosys Limited (INFY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs GeneDx Holdings Corp — how do they compare? Infosys Limited trades at $12.19 (market cap $50.55B), while GeneDx Holdings Corp trades at $81.63 (market cap $2.44B). The key difference: Infosys Limited is far larger — about 20.7× GeneDx Holdings Corp's market cap, and Infosys Limited pays a 4.16% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| INFY | WGS | |
|---|---|---|
Market Cap | $50.55B | $2.44B |
Sector | Technology | Technology |
52-Week High | $20.22 | $167.51 |
52-Week Low | $10.49 | $34.51 |
Enterprise Value | $48.30B | $2.48B |
Dividend Yield | 4.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.17, down 3.11% today, with mixed technical signals: a bullish moving average trend but overbought RSI levels. The company reported a Q2 2026 EPS miss but beat in prior quarters, maintaining strong profitability with a 16.37% net margin. Recent news highlights AI collaborations and a CEO transition, while institutional activity shows both buying and selling.
Outlook is cautious due to near-term revenue softness and lowered growth guidance, though solid cash flow and margins provide support. Risks include competitive pressures and macroeconomic headwinds. Analysts are mixed with a consensus price target of $11.05, suggesting limited upside from current levels.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
